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Abstract
Squamous cell lung cancer (SCC) and adenocarcinoma are the most common histological subtypes of non-small cell lung
cancer (NSCLC), and have been traditionally managed in the clinic as a single entity. Increasing evidence, however, illustrates
the biological diversity of these two histological subgroups of lung cancer, and supports the need to improve our
understanding of the molecular basis beyond the different phenotypes if we aim to develop more specific and
individualized targeted therapy. The purpose of this study was to identify microRNA (miRNA)-dependent transcriptional
regulation differences between SCC and adenocarcinoma histological lung cancer subtypes. In this work, paired miRNA (667
miRNAs by TaqMan Low Density Arrays (TLDA)) and mRNA profiling (Whole Genome 44 K array G112A, Agilent) was
performed in tumor samples of 44 NSCLC patients. Nine miRNAs and 56 mRNAs were found to be differentially expressed in
SCC versus adenocarcinoma samples. Eleven of these 56 mRNA were predicted as targets of the miRNAs identified to be
differently expressed in these two histological conditions. Of them, 6 miRNAs (miR-149, miR-205, miR-375, miR-378, miR-
422a and miR-708) and 9 target genes (CEACAM6, CGN, CLDN3, ABCC3, MLPH, ACSL5, TMEM45B, MUC1) were validated by
quantitative PCR in an independent cohort of 41 lung cancer patients. Furthermore, the inverse correlation between mRNAs
and microRNAs expression was also validated. These results suggest miRNA-dependent transcriptional regulation
differences play an important role in determining key hallmarks of NSCLC, and may provide new biomarkers for
personalized treatment strategies.
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Introduction
Lung cancer is the primary cause of cancer death worldwide,
being responsible for one million deaths annually [1]. Non-small
cell lung cancer (NSCLC) accounts for 80% of all lung tumours,
and includes several histological subtypes such as large cell
carcinoma (LCC), squamous cell carcinoma (SCC), and adeno-
carcinoma. SCC and adenocarcinoma are the most common types of
NSCLC, accounting for 25% and 40% of all cases, respectively
[2,3]. SCC derives from dysplastic multilayer epithelium in the
central airways, whereas adenocarcinoma originates preferentially
from precursor cells of the mono- or bilayer surface epithelium of
the lung periphery [4].
NSCLC, regardless of the histological subtype, has been traditionally
treated in the clinic as a single homogeneous entity. However,
increasing evidence illustrates the great biological diversity of this
disease, which is progressively leading to more specific diagnostic
and therapeutic strategies depending upon the histological subtype
concerned. Indeed, advances in targeted lung cancer therapy now
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demand accurate classification of NSCLC [5]. For example,
EGFR mutations are more prevalent in patients with lung
adenocarcinoma, and the presence of these mutations is associated
with sensitivity to EGFR tyrosine kinase inhibitors [6]. Similarly,
ALK traslocations, present in only 4% of adenocarcinomas, are
predictive of a high sensitivity to ALK-directed therapies such as
crizotinib. By contrast, FGFR1 amplification is more commonly
observed in SCC, and is now being considered a potentially
actionable target in clinical trials with FGFR inhibitors [7].
Therefore, a greater knowledge of the molecular mechanisms
involved in the genesis, progression and spread of the different
subtypes of NSCLC is necessary for the development of specific
diagnostic methods and the design of more adequate, individual-
ized and effective therapeutic strategies.
The great advances in genomic technologies have generated
many candidate biomarkers with potential clinical value in
NSCLC. MicroRNAs, as post-transcriptional modulators, are
key players in the regulation of many biological processes.
Dysregulation of their physiological roles contributes to many
pathological conditions, including the initiation and progression of
cancer. In this context, a number of studies have assessed the
potential role of miRNA signatures to discriminate histological
subtypes or to predict recurrence or survival of NSCLC patients
[8,9,10,11,12,13,14], and miRNA profiling has been proposed as a
highly reliable strategy for classifying NSCLCs [11,15,16].
Nevertheless, the high complexity of transcriptome regulation
complicates the full understanding of gene regulatory networks
involved in these processes.
To address this issue, the aim of this study was to assess miRNA-
dependent transcriptional regulation differences between SCC and
adenocarcinoma histological lung cancer subtypes. With this
purpose, miRNA and mRNA paired expression profiles were
analyzed in NSCLC tumor samples, and the potential interactions
among them were explored. In this study we have identified and
validated a subset of deregulated miRNAs and target genes that
are able to define distinct molecular features of these two major
histological subtypes of NSCLC.
Materials and Methods
Patients and Tumor Specimens
Patients included in this study were required to have
histologically confirmed early stage SCC or adenocarcinoma
NSCLC. Tumor samples from 85 patients were prospectively
collected during the surgical procedure and immediately snap-
frozen at 280uC until further use. Adjacent non-tumor lung tissue
was also collected from patients included in the validation cohort.
The study protocol was approved by the institutional review
boards of participating centers [Hospital Universitario Doce de
Octubre (Madrid) and Hospital Universitario Virgen del Rocı´o
(Sevilla)] and all patients provided written informed consent prior
to study entry. Clinical and pathologic data were extracted from
the medical records and centrally reviewed for the purpose of this
study. The study population was divided in a training cohort
(N= 44) that was used for profile development and an independent
validation cohort (N= 41). Main characteristics of study popula-
tion are summarized in Tables 1 and 2.
Microarray Gene Expression Profiles
Microarray experiments were performed using Human Whole
Genome 44 K array G4112A (Agilent technologies, Wilmington,
DE). RNA was isolated using Trizol (Invitrogen) and RNAesy
Extraction Kit (QIAGen, Germany) as indicated by the manu-
facturers. RNA was labeled and array hybridized using the Low
RNA Linear Amplification Kit and the In Situ Hybridization Kit
Plus (Agilent technologies, Wilmington, DE) respectively. After
hybridization and washing, the slides were scanned in an Axon
GenePix Scanner (Axon Instruments Inc., Union City, CA) and
analyzed using Feature Extraction Software 6.1.1 (Agilent
technologies, Wilmington, DE). RNA from tumor samples were
labeled with Cy5-dUTP, and hybridized against a lung cancer
reference pool (labeled with with Cy3-dUTP) consisting of primary
tumor tissue from patients with different histological subtypes of
lung cancer. As control, ten additional hybridizations were
performed using the reciprocal fluorochrome labeling.
To detect differentially expressed genes between the two
histological subtypes, two types of analysis were undertaken with
the MIDAW tool [17]. First, a t-test was performed with false
discovery rate (FDR) control estimated using the single-step
Bonferroni procedure. Genes that passed the t-test filter were
subjected to a second filter. Only genes showing a mean log ratio
value lower that 20.3 or greater than 0.3 (equivalent to a 2-fold
change) were selected as differentially expressed. Second, a
discriminant analysis for the identification of the set of best
marker genes was performed based on the Prediction Analysis of
Microarray (PAM) algorithm. Microarray raw data tables have
been deposited in the Gene Expression Omnibus under the
accession number of GSE42998.
MicroRNA qRT-PCR Assay
Total RNA, containing small RNA, was extracted from tumour
tissue samples by mirVana miRNA isolation kit (Ambion, Austin,
TX, USA) according to the manufacturer’s instructions. The total
RNA yield was determined using a Nanodrop ND-1000 spectro-
photometer (Nanodrop Tech, DE, USA). The Agilent 2100
Bioanalyzer was used to determine the quantity and quality of the
RNA samples (Agilent, Palo Alto, CA). Mature human miRNA
expression was detected and quantified using the TaqMan Low
Density Arrays (TLDA) based on Applied Biosystems’ 7900 HT
Micro Fluidic Cards (Applied Biosystems, CA, USA) according to
the manufacturer’s instructions. The Human MicroRNA Card Set
v2.0 array (Catalog Number 4400238) is a two card set containing
a total of 384 TaqMan MicroRNA Assays per card to enable
accurate quantification of 667 human microRNAs, all catalogued
in the miRBase database. TLDAs were performed in a two-step
process. Briefly, during the first step, 450 ng of total RNA were
reverse transcribed using Megaplex RT Primers and the TaqMan
miRNA reverse transcription kit in a total volume of 7.5 ml. The
7.5 ml reactions were incubated in a G-Storm Thermal Cycler
(Gene Technologies, Essex, UK) for 2 min at 16uC, 1 min at
42uC, and 1 min at 50uC during 40 cycles, held for 5 min at 85uC,
and then kept at 4uC. In the second step, 6 mL of cDNA sample
and TaqMan Universal PCR master mix were loaded in fill ports
on the TLDA microfluidic card. The card was briefly centrifuged
for 1 min at 331 g to distribute samples in the multiple wells
connected to the fill ports and then sealed to prevent well-to-well
contamination. The reactions were incubated in a 384 well plate at
50uC for 2 sec and 94.5uC for 10 min, followed by 40 cycles of
30 sec at 97uC and 1 min at 59uC. Finally, the cards were
processed and analyzed on an ABIPrism 7900 HT Sequence
Detection System. TLDA raw data tables have been deposited in
the Gene Expression Omnibus under the accession number of
GSE43000. Expression of target miRNAs was normalized to the
expression of RNU48. One non-human miRNA, was used in each
experiment as a negative control. Cycle threshold (Ct) values were
calculated using the SDS software v.2.3 using automatic baseline
settings and a threshold of 0.2. Relative quantitation of miRNA
expression was calculated by the 22DCt method (Applied
Transcriptional Regulation by MicroRNAs in NSCLC
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Biosystems user bulletin no. 2 (P/N 4303859)). Only miRNA
detectable in at least 80% of samples were considered for
evaluation. Significance of miRNA expression differences ob-
served between the two histolofical subgroups (adenocarcinoma
and SCC) was assessed by the t-test.
mRNA and miRNA Expression Correlation Assessment
To evaluate the potential association between differentially
expressed mRNA and miRNA observed in our study, we searched
for the transcriptional targets of the identified miRNAs in three
web databases for miRNA target prediction: miRanda [18],
TargetScan release 6.0 [19], and miRWalk [20]. Putative target
genes that matched with those found to be disregulated in our
patient population were selected for further validation by qPCR.
Validation of Microarray Gene Expression Profiles by
qPCR
Eleven differentially expressed genes among the two study
conditions (SCC and adenocarcinoma NSCLC), identified as
putative targets of several dis-regulated miRNAs, were selected for
further validation by qPCR in the original training cohort and
then in an independent validation cohort. The RNA was reverse
transcribed to cDNA with the High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems). Briefly, single-stranded
cDNA was synthesized from 1 mg total RNA in 10 mL reaction
volume, according to the manufacturer’s protocol. The reaction
was incubated at 25uC for 10 min followed by 120 min at 37uC
and inactivation at 85uC for 5 min. The TaqMan Gene
Expression Assay system (Applied Biosystems) was used for
quantitating transcription levels of selected genes (CEACAM6,
CGN, CLDN3, ABCC3, MLPH, ACSL5, TMEM45B, MUC1,
DMRT2, DSC3 and KRT6A). Three endogenous control genes
(B2M, ACTB and GAPDH) and one no-template-control (NTC)
were also run for each RNA sample. We chose B2M for
normalization across different genes as this gene showed the most
relatively constant expression across different tissue samples (data
not shown). The gene expression for each gene was determined
using the median expression level of the three technical replicates.
PCR reactions were performed on an Applied Biosystems 7900HT
Sequence Detection system in 10 mL volumes at 95uC for 10 min,
followed by 40 cycles of 95uC for 15 sec and 60uC for 1 min. Ct
values were obtained with the SDS software v.2.3 (Applied
Biosystems). Relative quantification of mRNA expression was
calculated by the 22DCt method (Applied Biosystems user bulletin
no. 2 (P/N 4303859)).
Validation of miRNA TLDA Expression Profiles by qPCR
Expression of nine selected miRNAs (miR-149, miR-205, miR-
375, miR-378, miR-422a, miR-483-5p, miR-494, miR-601 and
miR-708) was assessed in the independent validation cohort by the
specific TaqMan MicroRNA assays according to the manufactur-
er’s instructions (Applied Biosystems). Briefly, 2 ng/mL of total
Table 1. Summary of patients’ characteristics of the training cohort.
Variable Subvariable Squamous cell carcinoma (N = 25) Adenocarcinoma (N = 19)
Age years 71 [62–74] 65 [59–74]
Gender Male 25 (100%) 17 (89.4%)
Female – 2 (10.6%)
Stage I–IIB 17 (68%) 16 (84.2%)
IIIA 7 (28%) 2 (10.5%)
IIIB–IV 1 (4%) 1 (5.3%)
Smoking Status Current smoker 9 (36%) 7 (36.8%)
Ex-smoker 16 (64%) 10 (52.7%)
Never smoker – 2 (10.5%)
Continuous variables are expressed as median [interquartile range (IQR)] and categorical ones as number of cases (%).
doi:10.1371/journal.pone.0090524.t001
Table 2. Summary of patients’ characteristics of the validation cohort.
Variable Subvariable Squamous cell carcinoma (N = 25) Adenocarcinoma (N = 19)
Age years 66 [60–74] 66 [63–73]
Gender Male 15 (88.2%) 16 (66.7%)
Female 2 (11.8%) 8 (33.3%)
Stage I–IIB 15 (88.2%) 21 (87.5%)
IIIA 2 (11.7%) 2 (8.3%)
IIIB–IV – 1 (4.2%)
Smoking Status Current smoker 9 (52.9%) 6 (25.0%)
Ex-smoker 8 (47.1%) 15 (62.5%)
Never smoker – 3 (12.5%)
Continuous variables are expressed as median [interquartile range (IQR)] and categorical ones as number of cases (%).
doi:10.1371/journal.pone.0090524.t002
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RNA was converted into cDNA by reverse transcriptase reaction
that was performed by sequential incubation at 16uC for 30 min,
42uC for 30 min and 85uC for 5 min. PCR reaction mixture
(10 mL) contained 0.66 mL of RT product, 5 mL of TaqMan 2X
Universal PCR Master Mix and 0.5 mL of the appropriate
TaqMan MicroRNA Assay (20X) containing primers and probe
for the miRNA of interest (Applied Biosystems). The mixture was
initially incubated at 95uC for 10 min, followed by 40 cycles of
95uC for 15 seconds and 60uC for 60 seconds. MicroRNA
expression was quantified by the comparative 22DDCt method,
normalizing Ct values to RNU48. In the validation cohort, tumor
expression values were additionally normalized to expression
values in paired adjacent normal lung tissue.
39-UTR Reporter Assay for miR Target Validation
Confirmation of miR-149-binding to the 39 UTR of ABCC3
and of miR-378 and miR-422-binding to the 39 UTR of
TMEM45B. HEK 293 cells at 80% confluency were co-
transfected with luciferase reporter plasmids harboring the
complete 39-UTR of the desired gene (SwitchGear Genomics)
along with 100 nM of each miR-mimic or miRNA control
(Sigma). DharmaFECT Duo (Thermo Scientific) was used as the
transfection reagent in Opti-MEM (Life Technologies). Lumines-
cence was assayed 24 hours later using LightSwitch Assay
Reagents (SwitchGear Genomics) according to the manufacturer’s
instructions. Knockdown was assessed by calculating luciferase
signal ratios for specific miRNA/non-targeting control, using
empty reporter vector as control for non-specific effects. Each
experiment was performed in triplicate. t -test was performed for
wells from multiple experiments, and we compared mimic-
transfected cells with a mimic control for each gene vector.
Diagnostic Performance Assessment of Selected Genes
Diagnostic performance parameters were calculated for selected
genes in 2x2-contingency tables. Confidence intervals for these
parameters were calculated with the Pearson method based on the
F distribution. As sensitivity, specificity, Positive Predictive Value
(PPV) and Negative Predictive Value (NPV) are statistical
measures of the performance of a binary classification test, gene
expression values were converted to binary variables with the
median expression value as the reference value (high versus low
expression). These parameters were calculated for each validated
miRNA/target mRNA pair. The concurrent occurence of high
miRNA expression and low target mRNA expression in the
appropriate histological condition (SCC or adenocarcinoma) was
considered a true positive test. Sensitivity or true positive rate
measures the proportion of actual positives which are correctly
identified. Specificity or true negative rate measures the propor-
tion of negatives which are correctly identified. The PPV describes
the probability of having the condition given a positive screening
test result in the analyzed population. The NPV describes the
probability of not having the condition given a negative screening
test result in the analyzed population.
Results
Profile Development
Gene expression profiles by histological subtype. Whole
genome expression arrays were performed in tumor samples of
patients of the training cohort, and expression profiles of SCC and
adenocarcinoma tumor types were compared one gene at a time
using the one-sample t-test. After single-step Bonferroni adjust-
ment, 727 genes were identified to be differentially expressed by
more than two fold in either histological subtype relative to the
reference pool (Tables A, B, C and D in Table S1). Of these 727
genes, five were up-regulated and 195 down-regulated in patients
with adenocarcinoma, and 13 were up-regulated and 516 down-
regulated in patients with SCC.
Additionally, a second independent evaluation of mRNA
differential expression was performed by discriminant microarray
data analysis to minimize false-positive findings. The Prediction
Analysis of Microarray (PAM) algorithm identified 61 genes that
defined a molecular signature able to discriminate adenocarcino-
ma from SCC samples (figure 1). Of these 61 genes, 56 matched
deregulated genes found by the previously performed one-sample
t-test, and were therefore selected for further analysis and
validation.
MicroRNA expression profile by histological
subtype. MicroRNAs TLDA arrays were performed in tumor
samples of patients of the training cohort. Nine miRNAs (miR-
149, miR-205, miR-375, miR-378, miR-422a, miR-483-5p, miR-
494, miR-601 and miR-708) were found to be differentially
expressed between the SCC and adenocarcinoma histological
subtypes by a FDR-corrected threshold of 0.05. Eight of these 9
miRNAs were over-expressed in SCC compared to adenocarci-
noma, and one (miR-375) was over-expressed in adenocarcinoma
compared to SCC (Table 3).
MicroRNA target prediction. Eleven of the 56 genes (20%)
found to be deregulated by tumor type in our study were found to
be putative targets of at least one of the 9 miRNAs also identified
to be differentially expressed in our study population according to
histological subtype (SCC versus adenocarcinoma). For the 8 over-
expressed miRNAs in SCC, 8 mRNA (CEACAM6, CGN, CLDN3,
ABCC3, MLPH, ACSL5, TMEM45B and MUC1) were predicted as
targets by several algorithms. These genes were found to be down-
regulated in SCC compared to adenocarcinoma in our study
(Table 2). Three of these 8 genes (CEACAM6, MLPH and
TMEM45B) were predicted targets of more than one of these
miRNAs (figure 2). As shown in table 2, three genes (DSC3, KRT6A
and DMRT2) were predicted as targets of miR-375, the miRNA
upregulated in adenocarcinoma, and these genes were consistently
down-regulated in this histological subtype.
Profile Validation
Validation of gene differential expression by quantitative
RT-PCR. Eleven deregulated genes (CEACAM6, CGN, CLDN3,
ABCC3, MLPH, ACSL5, TMEM45B, MUC1, DSC3, DMRT2 and
KRT6A), identified as putative target genes of deregulated
miRNAs in our study, were then selected for further validation
by rtPCR both in the training cohort and in an independent
cohort of patients.
In the training cohort, 9 of the 11 genes tested were confirmed
to be differentially expressed by histological subtype by quantita-
tive PCR (figure 3). CEACAM5, CLDN3, CGN, ABCC3, MUC1,
ACSL5, MLPH and TMEM45B were significantly down-regulated
in SCC, and KRT6A was significantly down-regulated in
adenocarcinoma.
Based on results obtained in the training cohort, 9 mRNA and 9
miRNAs were selected for further validation by Taqman-based
RT-qPCR in tumor and matched normal tissue from an
independent cohort of lung cancer patients. In this cohort,
expression patterns of mRNAs were consistent with those
quantified in the training cohort. Expression patterns by histolog-
ical subtype of all 9 mRNAs tested resembled those observed in the
training cohort, and differences observed among subgroups were
all statistically significant (figure 4). Regarding the 9 miRNAs, five
(miR-149, miR-205, miR-378, miR-422a and miR-708) were
Transcriptional Regulation by MicroRNAs in NSCLC
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Figure 1. Distinct transcriptional profiles of SCC and adenocarcinoma histological subtypes. The Prediction Analysis of Microarray
algorithm identified 61 genes that defined a molecular signature for each histological subtype. The modulators’ dendrogram represents an
unsupervised hierarchical clustering analysis of 19 adenocarcinoma and 25 SCC based on their gene expression profile. The heat map was color
coded using red for up-regulation and green for down-regulation from a lung cancer reference pool. On the top of the heap map, colours correspond
to gene expression profiles of SCC samples (blue) versus adenocarcinoma samples (red).
doi:10.1371/journal.pone.0090524.g001
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Table 3. Identification of down-regulated mRNA from deregulated miRNAs in SCC and adenocarcinoma.
Target genes predicted Prediction programs
Over-expressed miRNAs in SCC
miR-149 ABCC3 miRanda, miRWalk, TargetScan
MUC1 TargetScan
CEACAM6 miRanda, miRWalk, TargetScan
CGN miRanda
CLDN3 miRanda
miR-205 ACSL5 miRanda, TargetScan
MLPH miRWalk, TargetScan
CEACAM6 miRanda, miRWalk, TargetScan
miR-378 TMEM45B miRanda
miR-422a TMEM45B miRanda
miR-483-5p TMEM45B miRanda, TargetScan
miR-494 ACSL5 TargetScan
MLPH miRanda
CEACAM6 miRanda
miR-601 MLPH miRanda, miRWalk, TargetScan
miR-708 CEACAM6 miRanda, TargetScan
Over-expressed miRNAs in adenocarcinoma
miR-375 DSC3 miRanda, miRWalk, TargetScan
KRT6A miRanda
DMRT2 miRanda, miRWalk
doi:10.1371/journal.pone.0090524.t003
Figure 2. MicroRNA-mRNA target networks. The graph shows the transcriptional targets of differently expressed miRNAs in SCC and
adenocarcinoma tumor types using three web databases of miRNA target prediction (miRANDA, TargetScan and miRWalk). The default colour
scheme used to represent expression level is red/blue (red for over-expression of mRNAs or miRNAs in SCC versus adenocarcinoma and blue for
down-expression of mRNAs or miRNAs in SCC versus adenocarcinoma). The arrows indicate mRNA repression by the connected miRNAs. Squares
represent deregulated mRNAs and ovals represent differentially expressed miRNAs in lung adenocarcinoma and SCC.
doi:10.1371/journal.pone.0090524.g002
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found to be significantly over-expressed in SCC and miR-375 was
significantly over-expressed in adenocarcinoma (figure 5).
Correlation between miRNA and mRNA expression. To
study the functional relevance of miRNAs in the regulation of
specific mRNAs identified as potential biomarkers, we analyzed in
the validation cohort the correlation between miRNAs and
predicted target-mRNAs expression in each patient (figure 6).
An inverse correlation was observed between ABCC3, MUC1 and
CEACAM6 and miR-149 expression levels. Moreover, higher levels
of CEACAM6 were associated with lower levels of miR-205 and
miR-708, being the correlation significant for miR-708 (r =2
0362; p= 0.030). ACSL5 and KRT6A had a statistically significant
correlation with miR-205 (r =20.475; p= 0.003) and miR-375
(r =20.311; p = 0.065), respectively. In the case of TMEM45B,
significant correlations were found for miR-378 and miR-422a (r =2
0.394, p = 0.016 and r =20.413, p = 0.015, respectively). These
results suggest a potential role of miRNAs in the regulation of
these genes. Subsequently, some of these targets were tested using
luciferase reporter gene assays. We achieved that overexpression of
miR-149 in HEK 293 cells down regulates the luciferase activity of
reporter construct containing the ABCC3 3-UTR (figure 7). This
shows that miR-149 binds directly to this target RNA and inhibits
their expression. In addition, overexpression of miR-378 and miR-
422a significantly inhibit TMEM45B expression (figure 7).
Diagnostic Performance of Selected Genes to
Discriminate SCC from Adenocarcinoma Histological
NSCLC Subtypes
Finally, we evaluated the specificity and sensitivity of these six
validated miRNAs in combination with their predicted mRNAs to
discriminate between SCC and adenocarcinoma (figure 8). The
best performance was observed for KRT6A, as a target of miR-375,
with sensitivity and specificity values of 94.1% and 88.9%,
respectively. Good diagnostic performance was also observed for
CEACAM6, ACSL5 y MLPH, as targets of miR-205, with lower
specificity values (71.4–76.2%) but higher sensitivity (100%).
Figure 3. Experimental validation of deregulated mRNA in the training cohort. To validate genes identified as differentially expressed by
tumor histology in the microarray data, relative expression levels of mRNAs were quantified by real-time PCR using the DCt method by B2M as
housekeeping gene. The plots show median DCt values of validated genes in patients with adenocarcinoma versus SCC. Data derived from RT-qPCR
are presented as log2 2
2DCt values. P value below 0.05 was considered significant.
doi:10.1371/journal.pone.0090524.g003
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Finally, TMEMB45B, as target of miR-378, showed a sensitivity of
87.5% and a specificity of 57.7%. The other miRNA/mRNA
couples revealed lower sensitivity and specificity values, although
they were greater than 75% and 50% in all cases, respectively
(Table S2).
Discussion
In this study we analyzed the mRNA and miRNA expression
signatures of patients with different subtypes of NSCLC. This
allowed us to construct a robust transcriptional profile of lung
adenocarcinoma and SCC. Our results not only indicate the
existence of a mRNA and/or miRNA expression patterns that are
able to distinguish between SCC and adenocarcinoma, but also
that the altered gene expression signature is partly caused by
specific miRNA deregulation.
First, we analyzed by two approaches the whole genome
expression microarray data to minimize false positives. We
examined differential gene expression levels by discriminate
microarray data analysis and by the one-sample t-test. Fifty-six
genes were found to be significantly deregulated by both analyses
and were therefore selected for further evaluation and validation.
Remarkably, several of them had been previously implicated in
relevant biological processes (according to gene ontology) in lung
cancer. For example, some genes of the KRT family, which were
down-regulated in adenocarcinoma, are involved in several critical
cell functions such as cell migration, growth and proliferation [21].
Second, miRNA profiling identified 9 miRNAs that were
Figure 4. Validation of deregulated mRNA in an independent cohort. Expression of nine mRNAs was validated by real-time PCR in an
independent cohort of NSCLC patients. mRNA expression levels were determined in tumor samples and paired normal lung tissue from lung cancer
patients and relative expression by histological subtype was assessed. Median DDCt values were determined in the validated genes in patients with
adenocarcinoma and SCC. Data derived from RT-qPCR are presented as 22DDCt values. P value below 0.05 was considered significant.
doi:10.1371/journal.pone.0090524.g004
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differentially expressed among the two histological subtypes of
NSCLC studied. Six of them (miR-149, miR-205, miR-375, miR-
378, miR-422a and miR-708) were further validated in an
independent cohort of NSCLC patients as biomarkers able to
discriminate adenocarcinoma and SCC. To assess whether these
miRNAs could be directly regulating some of the 56 deregulated
genes identified, several broadly used algorithms were used. Eleven
of these 56 genes (20%) were thus predicted to be putative targets
of at least one of the six miRNAs found to be differentially
expressed in SCC compared to adenocarcinoma. Moreover, some
of the predicted target genes were regulated by more than one of
these miRNAs. Finally, nine (82%) of the 11 target genes were
further validated by qRT-PCR in the initial training set of 44
patients and subsequently in an independent validation cohort.
Other mechanisms (i.e. epigenetic regulation) are likely involved in
the regulation of the remaining differentially expressed genes.
Functional studies indicate that miRNAs participate in the
regulation of almost every cellular process investigated and that
changes in their expression are observed in diseases such as cancer.
Bioinformatic predictions indicate that mammalian miRNAs can
regulate approximately 30% of all protein-coding genes [22].
Thus, post-transcriptional regulation by microRNA may be
involved in the development of the different histological pheno-
types of NSCLC, and these miRNA/mRNA couples identified
may prove to be useful tools for diagnostic purposes or as potential
novel targets for lung cancer therapy. Consistent with this, 2 of the
6 miRNAs we validated in our study (miR-205 and miR-708) had
been proposed by other investigators, in combination with miR-
Figure 5. Relative quantification of deregulated microRNAs in the independent validation cohort. Expression of deregulated miRNAs
was evaluated in the validation cohort. MicroRNA expression levels were determined in tumor and paired normal lung tissue of lung cancer patients
and relative expression by histological subtype was assessed. Median DDCt values were determined in nine miRNAs in patients with adenocarcinoma
versus SCC. Data derived from RT-qPCR are presented as 22DDCt values. P value below 0.05 was considered significant.
doi:10.1371/journal.pone.0090524.g005
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210, as biomarkers to improve the early detection of SCC [23,24].
In addition, Huang et al. found recently that miR-375 along with
miR-29a accurately discriminate squamous cell lung cancer from
NSCLC [25].
To date, several protein profiles have been proposed for
classifying NSCLC, including TTF1, napsin A, p63 and KRT5/6
or TRIM29, CEACAM5, SLC/A5, MUC1 and KRT5/6, among
others [26,27]. In our work, mRNA expression levels of
CEACAM6, CGN, CLDN3, ABCC3, MLPH, ACSL5, TMEM45B
and MUC1, were significantly lower in SCC compared to
adenocarcinoma. Some of these genes are involved in cell-cell
adhesion which is a critical process in the formation and
maintenance of tissue patterns during development, and also a
critical process during invasion and metastasis, one of the
hallmarks of cancer [28,29,30,31].
CEACAM6 is an intercellular adhesion molecule that is over-
expressed in a wide variety of human tumours and represents an
important determinant of cancer progression [32,33,34,35]. Over-
expression of CEACAM6 has been reported to affect cell
migration, cell invasion, and cell adhesion in vitro, and agents
blocking CEACAM6 decreased the number of migrating cells in
preclinical models [28]. Furthermore, over-expression of CEA-
CAM6 is associated with a poorer prognosis of patients with
colorectal adenocarcinoma following surgical resection, and is a
very useful marker for the follow-up of these patients in the clinic
[36]. Duxbury et al. have demonstrated that CEACAM6 plays a
significant role in anoikis resistance [37]. Regarding lung cancer,
and consistent with our observations, other investigators have
reported higher CEACAM6 expression levels in adenocarcinoma as
compared to SCC tumours [34]. Moreover, CEACAM6 is a
putative target for 3 of the miRNAs found to be upregulated in
SCC in our study (miR-149, miR-205 and miR-708).
On the other hand, we have showed that adenocarcinoma
phenotype is associated with a higher expression of CLD3 and
CGN, whereas SCC often loses the expression of these genes.
These genes are not likely regulated by miRNAs. CLDN3 and
Figure 6. Spearman’s correlation between miRNA and target gene expression in patients with lung adenocarcinoma or squamous
cell carcinoma. Expression of the 6 validated miRNAs and that of their putative target genes was measured in each patient in the validation cohort.
The significance of the inverse association between each of these miRNA/mRNA couples was assessed by the Spearman’s correlation coefficient. P
values less than 0.05 were considered statistically significant. A) Relationships between ABCC3, MUC1 and CEACAM6 with miR-149. B) Relationships
between ACSL5 and CEACAM6 with miR-205. C) Relationship between TMEM45B and miR-378. D) Relationship between TMEM45B and miR-422a. E)
Relationship between CEACAM6 and miR-7018. F) Relationship between KRT6A and miR-miR-175.
doi:10.1371/journal.pone.0090524.g006
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CGN are involved in tight junctions, which are a hallmark of
polarized epithelial cells, providing a barrier to control the
diffusion of integral membrane proteins from apical to basolateral
membrane surfaces [29,30,31].
ABCC3 is a member of the superfamily of ATP-binding
cassette (ABC) transporters. Several ABC transporters are linked
to lung cancer, such as ABCC1, ABCC3, ABCA3 and ABCC5
[38]. ABCC3 is a member of the MRP subfamily which is
involved in multi-drug resistance to chemotherapeutic agents,
playing a major role in the failure of cancer therapy [39].
O’Brien et al. identified that ABCC3 amplification correlates with
lack of clinical benefit from taxane-containing regimens in
HER2-amplified breast cancer [40]. In addition, a small set of
nine gene-signatures, in which ABCC3 is included, has been
recently proposed for sub-classification of NSCLC [41]. In our
study, we found that ABCC3 expression was higher in adeno-
carcinoma than in SCC and found that the expression of this
gene may be regulated by miRNA-149. Therefore, the ABCC3
gene could serve as a predictive biomarker of response to
chemotherapy in this subtype of NSCLC. Nonetheless, these
results need to be validated in larger prospective cohorts to
adequately address their clinical application.
Mucine-1, MUC1, is a transmembrane glycoprotein that is
normally expressed on the apical surface of mammary epithelial
cells. Nevertheless, its aberrant expression has been observed in
patients with tumours of glandular epithelial origin, as breast,
ovary, lung, and prostate cancers, among others [42]. Therefore,
this protein could be a potential target for therapeutic interven-
tions in cancer. Moreover, the detection of MUC1 has been linked
to the simultaneous expression of multiple angiogenic factors (as
VEGF) and with an aggressive tumour behaviour [43,44,45,46].
In addition, there is convincing evidence that this oncoprotein
confers resistance to genotoxic anticancer agents [47]. On the
other hand, it is interesting to note that MUC1 in combination
with other proteins have been proposed as immunohistochemical
tests for subclassification of lung adenocarcinoma and SCC [26].
Here, we found also higher expression levels of MUC1 in lung
adenocarcinoma than in SCC tumours. In addition, we observed
that the low levels of transcripts in SCC was associated with higher
expression levels of miR-149.
At the present time, the precise functions of ACSL5, MLPH
and TMEM45B in cancer remain unknown. ACSL5 is a member
of the ACS family, which converts fatty acid to acyl-CoA. This
protein is highly expressed in uterus and spleen, and in trace
amounts in normal brain, but has markedly increased levels in
malignant gliomas [48]. Moreover, it has been described that
ACSL5 plays a dominant role in vitro in the biosynthesis of
mitochondrial cardiolipin and could be involved in cancer cell
survival [49]. In the case of MLPH, this protein is involved in the
transport of melanosomes [50]. Overexpression of MLPH has
been observed in epithelial-enriched tissues in mice, such as
kidney, lung, skin, small intestine, and stomach [50]. MLPH is the
only trafficking protein known to be regulated by aldosterone at
transcriptional level. In our study, we observed that these genes
were up-regulated in adenocarcinoma versus SCC. ACSL5 may be
regulated by miR-205. However, we could not confirm a
significant association between MLPH and miR-205 expression.
Figure 7. 39-UTR reporter assay for miR target validation. HEK 293 cells were transfected with luciferase reporter vector containing the 39 UTR
region of ABCC3 and TMEM45B. Reporter vectors were co-transfected with a miRN mimic or control miRN mimic. Following 24 h incubation,
luciferase activity was measured. *p,0.05 and **p,0.001 by t-test.
doi:10.1371/journal.pone.0090524.g007
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On the other hand, TMEM45B expression levels were negatively
correlated with expression levels of miR-378 and miR-422a.
In our work, the inverse relationship between miR-375 and
KRT6A expression levels was consistently observed across histol-
ogies. The expression of this gene was significantly increased in
SCC versus adenocarcinoma. Consistent with this finding, KRT6A
is related with the maintenance of the epidermal integrity. Indeed,
KRT6A is a member of the keratin protein family and is related to
the epidermalization of squamous epithelium [51].
In conclusion, we have identified and validated miRNA-
dependent mRNA distinct profiles able to discriminate between
SCC and adenocarcinoma histological subtypes of NSCLC. The
present results contributes to the progress of our understanding of
the molecular pathogenesis of lung cancer and may provide
important evidence to improve classification of poorly differenti-
ated NSCLC, as well as potential novel biomarkers for person-
alized treatment strategies.
Supporting Information
Table S1 Differentially expressed genes in SCC and adenocar-
cinoma relative to the reference pool. T-test was performed with
false discovery rate (FDR) control estimated using the single-step
Bonferroni procedure. Genes that passed the t-test filter were
subjected to a second filter. Only genes showing a 2-fold change
were selected as differentially expressed.
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Table S2 The specificity and sensitivity of validated miRNAs in
combination with their predicted mRNAs to discriminate between
SCC and adenocarcinoma. Sensitivity measures the proportion of
actual positives which are correctly identified and specificity
measures the proportion of negatives which are correctly
identified. The PPV describes the probability of having the
condition given a positive screening test result in the analyzed
population. The NPV describes the probability of not having the
condition given a negative screening test result in the analyzed
population.
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